Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23489210 | 0.87 | ITGB1 (0.45) | ACECASP3MGLLPOLBMEN1 | |
| SCHEMBL23489260 | 0.86 | TAS1R3 (0.43) | MEN1KMT2AITGB1ITGA5 | |
| SCHEMBL23489207 | 0.86 | TAS1R3 (0.43) | MEN1KMT2AITGB1ITGA5 | |
| SCHEMBL23489408 | 0.83 | ITGB1 (0.48) | MEN1KMT2AITGB1ITGA5 | |
| SCHEMBL23489479 | 0.83 | ITGB1 (0.42) | ACECASP3POLBMAPTITGB1 | |
| SCHEMBL23489231 | 0.82 | ITGB1 (0.52) | ACECASP3TACR1RAB9AMEN1 | |
| SCHEMBL26478066 | 0.81 | ITGB1 (0.46) | MEN1KMT2AITGB1ITGA5 | |
| SCHEMBL23978758 | 0.80 | SYK (0.53) | POLBPPARAMEN1MAPTKMT2A | |
| SCHEMBL23489597 | 0.77 | MEN1 (0.41) | MGLLNPC1RAB9AMEN1MAPT | |
| SCHEMBL29017554 | 0.76 | CTSK (0.56) | TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | ACE 1928/4885CASP3 3587/4885MGLL 4280/4885 |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | ACE 603/4885CASP3 3714/4885MGLL 2574/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | ACE 1928/4885CASP3 3587/4885MGLL 4280/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ACE 603/4885CASP3 3714/4885MGLL 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.